Linzagolix (Yselty®). HTA ID: 23068

Assessment Status Awaiting full HTA submission from Applicant
HTA ID 23068
Drug Linzagolix
Brand Yselty®
Indication Linzagolix is indicated for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.
Assessment Process
Rapid review commissioned 09/11/2023
Rapid review completed 19/12/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of linzagolix compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 31/01/2024
Pre-submission consultation with Applicant 16/04/2024